Abstract Number: L10 • ACR Convergence 2023
Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…Abstract Number: L18 • ACR Convergence 2023
Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands
Background/Purpose: Primary Sjögren's syndrome (pSS) is a complex autoimmune disease with significant heterogeneity. Our study aimed to clarify the etiology and molecular variation of the…Abstract Number: 0008 • ACR Convergence 2023
Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice
Background/Purpose: Sjögren's Disease is an autoimmune condition in which patients exhibit decreased salivary/lacrimal gland function and express autoantibodies that target the 60k molecular weight Ro…Abstract Number: 1251 • ACR Convergence 2023
Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital
Background/Purpose: The prevalence of Sjogren's disease (SD) is becoming increasingly recognized in pediatric rheumatology. Despite fewer sicca symptoms, it has been shown that pediatric SD…Abstract Number: 1378 • ACR Convergence 2023
The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study
Background/Purpose: In clinical trials investigating new drugs for the management of Interstitial Lung Disease (ILD) patient reported outcomes (PRO) are increasingly employed as outcome measures…Abstract Number: 2179 • ACR Convergence 2023
Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey
Background/Purpose: Sjögren's disease (SjD) is a debilitating disease that has been shown to impact patients' quality of life (QoL). Though oral and ocular dryness are…Abstract Number: 2260 • ACR Convergence 2023
Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Background/Purpose: Fatigue is a common symptom in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Resting-state functional magnetic resonance imaging (rs-fMRI) has…Abstract Number: 0020 • ACR Convergence 2023
The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterised by glandular involvement of the eye and salivary glands, leading to xerostomia and xerophthalmia. In…Abstract Number: 1253 • ACR Convergence 2023
The Novel Florida Scoring System: A Machine Learning-Based Stratification of Clinical and Laboratory Features in Children with Suspected Sjögren’s Disease
Background/Purpose: Childhood Sjögren 's disease (cSjD) is a poorly defined systemic autoimmune disorder. Due to the absence of diagnostic criteria, heterogeneous presentations, and the dissimilarity…Abstract Number: 1379 • ACR Convergence 2023
Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome
Background/Purpose: Sjögren's (SjS) is a chronic, systemic autoimmune disease caused by aberrant activation and infiltration of lymphocytes. Dazodalibep (DAZ), a novel non-antibody biologic antagonist of…Abstract Number: 2180 • ACR Convergence 2023
Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome
Background/Purpose: Since mitochondrial double-stranded RNAs (mt-dsRNAs), an endogenous activator of interferon signaling, are elevated in primary Sjӧgren's syndrome (pSS), we evaluated their association with the…Abstract Number: 2335 • ACR Convergence 2023
Defining a Basket Population for ANA+ Arthritis Trials
Background/Purpose: Musculoskeletal (MSK) manifestations are common in systemic lupus erythematosus (SLE) and other ANA-associated rheumatic musculoskeletal diseases (ANA-RMDs). Presently clinical trials recruit patients from individual…Abstract Number: 0037 • ACR Convergence 2023
New Histological Approach in Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease
Background/Purpose: 10X Visium spatial transcriptomics evaluates gene expression in a 50μm tile coordinate of a sectioned tissue, yielding heterogeneous cell sampling. Spatial PCA algorithm was…Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…Abstract Number: 1380 • ACR Convergence 2023
Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes
Background/Purpose: Immune-related genes located on the X chromosome are known to be important in the regulation of sex hormones and immune tolerance. It has been…
- 1
- 2
- 3
- …
- 12
- Next Page »